'Do not eat': Popular snacks recalled in the UK due to salmonella contamination
The Wall's classic Scotch Egg and the two pack of the classic scotch egg have been recalled as a result of salmonella being found in the products.
A spokesman for the Food Standards Agency said: 'The Compleat Food Group is recalling the above products.
'Point of sale notices will be displayed in all retail stores that are selling these products.
1 July: @The Compleat Food Group recalls Wall's The Classic Scotch Egg and Wall's 2 Classic Scotch Eggs because of contamination with Salmonella #FoodAlert https://t.co/s2GfMJOpZP pic.twitter.com/gX05pyBB6C
— Food Standards Agency (@foodgov) July 1, 2025
'These notices explain to customers why the products are being recalled and tell them what to do if they have bought the products.
'If you have bought any of the above products do not eat them.
'Instead, return them to your nearest store for a full refund. For more information email CUSTOMERCARE@COMPLEATFOOD.COM.'
The affected scotch eggs have a use by date of July 2.
A spokesman for The Compleat Food Group added: 'We are voluntarily recalling these Wall's products with a use by date of July 2 only due to a potential risk of salmonella.
'This is an isolated incident and no other Wall's products are affected.'
Asda, Matalan and Amazon recalls as shoppers told 'stop using them immediately'
FSA issues 'do not eat' warning over chocolate that may be a 'food safety risk'
'Do not eat' warning issued as 'unsafe to eat' sweets recalled
If there is a problem with a food product that means it should not be sold, then it might be 'withdrawn' (taken off the shelves) or 'recalled' (when customers are asked to return the product).
The FSA issues Product Withdrawal Information Notices and Product Recall Information Notices to let consumers and local authorities know about problems associated with food.
In some cases, a 'Food Alert for Action' is issued.
This provides local authorities with details of specific actions to be taken on behalf of consumers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Enrolment concludes in Belite Bio's trial of Tinlarebant for geographic atrophy
Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant in individuals with geographic atrophy (GA) in dry age-related macular degeneration (AMD). This multicentre, randomised, placebo-controlled, double-masked, global trial is crucial in evaluating the therapy's potential to minimise the atrophic lesion growth rate in these patients. It has enrolled 500 participants across various sites in the US, the UK, the Czech Republic, France, Switzerland, Taiwan, Australia, and China. Tinlarebant, a one-daily tablet, is being developed as an early intervention to preserve retinal tissue health and integrity in those with Stargardt disease type 1 (STGD1) and GA. At present, there are no treatments approved by the Food and Drug Administration (FDA) for STGD1 and no approved oral treatments for GA. The tablet has received fast track, rare paediatric disease, and breakthrough therapy designations in the US, orphan drug status in the US, Japan, and Europe, and Sakigake designation in Japan for STGD1. Tinlarebant is also being evaluated in a Phase III trial (DRAGON) and a Phase II/III trial (DRAGON II) for adolescent STGD1 individuals, in addition to the PHOENIX trial for GA subjects. Belite Bio CEO and chairman Dr Tom Lin said: 'Completing enrolment in the PHOENIX trial marks an important milestone for Belite Bio as we advance our lead candidate, Tinlarebant, for the treatment of geographic atrophy. 'This achievement brings us one step closer to evaluating the potential of Tinlarebant to slow atrophic lesion growth in this serious and progressive disease for which there are no approved oral treatments. There remains a significant unmet need for this patient population.' The company develops new treatments for degenerative retinal diseases like STGD1 and GA. Last year, the company submitted an application to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to initiate a trial of Tinlarebant for adolescent STGD1 treatment. "Enrolment concludes in Belite Bio's trial of Tinlarebant for geographic atrophy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Ministers face backbench calls to widen access to top tier of sickness benefits
Ministers are facing Labour backbench calls to widen access to their proposed top tier of sickness benefits. Labour backbencher Graeme Downie has proposed a welfare reform Bill amendment, so universal credit claimants with Parkinson's or multiple sclerosis who cannot work do not face repeated medical assessments to receive a payout. If MPs back his amendment, patients with 'evolving' needs who cannot work could also qualify for a higher rate of benefits. The Government's Bill has already cleared its first Commons hurdle at second reading, after work and pensions minister Sir Stephen Timms vowed not to restrict eligibility for the personal independence payment (Pip), with any changes coming in only after a review of the benefit. To meet his promise, ministers have had to table amendments to their own draft new law, to remove one of its seven clauses, which MPs will debate next Wednesday. Universal credit claimants with Parkinson's 'are already possibly struggling financially', Mr Downie told the PA news agency ahead of the debate. He added: 'The cost of living with a condition like Parkinson's can be very high. 'You may well require or need additional support.' The Dunfermline and Dollar MP said patients who struggle with their motor control might buy pre-chopped vegetables or chicken. 'Those things are expensive, so if you're already on universal credit and you're struggling, being able to do that significantly impacts your health, it significantly impacts your ability to live properly,' he continued. As part of the Government's reforms, the Department for Work and Pensions has proposed a new 'severe conditions criteria' for universal credit. Claimants in this category will be entitled to a higher rate of the benefit, and will not be routinely reassessed to receive money. To qualify, claimants must have limited capability for work or work-related activity (LCWRA) and symptoms which 'constantly' apply. Mr Downie's amendment would expand these criteria to claimants with 'a fluctuating condition'. It would cover 'conditions like Parkinson's but also multiple sclerosis, ME (myalgic encephalomyelitis), long Covid and a whole range of other conditions where, you know, in the morning things could be really good and in the afternoon things could be really bad, and even hour by hour things could change', he said. 'I felt it was necessary to table an amendment to really probe what the Government's position is on this, and ensuring that people with Parkinson's and conditions like that are not excluded from even applying and being considered.' Mr Downie's proposal has backing from 23 cross-party MPs. Juliet Tizzard, external relations director at Parkinson's UK, said: 'Criteria in the Bill say that a new claimant for the universal credit health payment will have to be 'constantly' unable to perform certain activities to qualify. 'This doesn't work for people with Parkinson's, whose symptoms change throughout the day. 'People with Parkinson's and other fluctuating conditions like multiple sclerosis will be effectively excluded from getting all the financial support they need. 'The Government has responded to our call and withdrawn the damaging restrictions to Pip. 'Now, they must do the same with the universal credit health element. The health of many people with Parkinson's is in their hands.'
Yahoo
an hour ago
- Yahoo
Man kicks off 55-marathon challenge in city
A man is set to run 55 marathons in one year, starting in Hereford. Adam Rodriguez, 28, from Bath, is undertaking this challenge to raise funds for a cancer charity, inspired by his mother's fight against cancer. Starting his first marathon in Hereford on July 5, Adam will run in 55 English cities, concluding in Salisbury in June 2026. The runs will all be on weekends, as Adam works full-time, and he plans to track his progress using a Strava device. Mr Rodriguez said: "A few years ago my mother bravely battled large B-cell lymphoma in three places and while she survived, the journey tested every part of our family." He wants to raise money for Move Against Cancer, a charity that supports people affected by cancer. He is keen to meet participants and ambassadors of Move Against Cancer's 5k Your Way initiative during his challenge. He said: "It's going to be such an honour joining the participants and ambassadors of 5KYW across the country. "These are the people creating community, encouragement and strength at a local level and I'm excited to hear their stories, share the miles with them, and highlight the real impact Move Against Cancer is making on the ground." He admits the real challenge will be recovery, especially on weekends with consecutive marathons. Despite this, he remains optimistic about completing his goal. You can donate to his JustGiving page here. His mother, Sharon, is fully supportive and confident in his success. Sophie Mulligan, MOVE Against Cancer's fundraising officer, said: "He's given up a whole year of weekends to take on this epic challenge and to do it in support of MOVE Against Cancer means so much to us."
